

CONTENTS

Section	Description	Pg. No.
Contents		I – VI
List of Tables		VII – VIII
List of Figures		IX – XI
Abbreviations		XII – XIII
Chapter 1: Introduction		1 – 14
1.1.	Uterine Disorders	1
1.1.	Endometrial cancer (EC)	1
1.1.1.	Statistics	1
1.1.2.	Risk factors	1
1.1.3.	Treatment Modalities	2
1.1.4.	Chemotherapy	2
1.2.	Mechanism of Action	3
1.2.1.	Paclitaxel	3
1.2.2.	Carboplatin	3
1.3.	Presently available forms of Paclitaxel and carboplatin and limitations thereof	3
1.4.	Importance of Tumour Targeting	5
1.4.1.	Approaches for targeting	5
1.5.	Vaginal Route for drug administration	6
1.6.	First Uterine Pass Effect	6
1.7.	Formulation Development	7
1.7.1.	Ultra deformable vesicles	7
1.8.	Aim and Objectives	9
1.9.	Hypothesis	9
1.10.	Plan of work	9
Chapter 2: Literature Review		15 – 51
2.1.	Anatomy and Physiology of Human Uterus	15
2.1.1.	Structure of Uterus	15
2.1.2.	Uterine Vasculature	17
2.2.	First Uterine Pass Effect (FUPE)	19
2.3.	Endometrial Cancer	22
2.3.1.	Pathology of the Endometrial Cancer	23
2.4.	Management of endometrial cancer	24
2.4.1.	Surgical Principles in Endometrial Cancer	24
2.4.2.	Chemotherapy in Endometrial Cancer	25
2.4.2.1.	Paclitaxel (PTX)	26
2.4.2.2.	Carboplatin (CBP)	31
2.5.	Vaginal Route for Drug Delivery	35
2.6.	Ultra deformable nano vesicles (UDNVs)	39
2.7.	Quality by Design (QbD) in Formulation	43

Section	Description	Pg. No.
2.7.1.	Statistical Designs in Formulation Optimization	44
Chapter 3: Analytical Methods		53 – 65
3.1.	Introduction	53
3.2.	Materials and Instruments	53
3.2.1.	Materials	53
3.2.2.	Instruments	53
3.3.	Analytical Method for Estimation of PTX	54
3.3.1.	Chromatographic setup	54
3.3.2.	Mobile Phase Preparation	54
3.3.3.	Preparation of Stock solution	54
3.3.4.	Preparation of standard solutions	55
3.3.5.	Preparation of calibration plot	55
3.3.6.	Validation of HPLC method	55
3.3.6.1.	Linearity	55
3.3.6.2.	Precision	56
3.3.6.3.	Accuracy	56
3.3.6.4.	Sensitivity	56
3.4.	Results and Discussion	57
3.4.1.	Preparation of calibration plot	57
3.4.2.	Validation of HPLC Method	58
3.4.2.1.	Linearity	58
3.4.2.2.	Precision	58
3.4.2.3.	Accuracy	59
3.4.2.4.	Sensitivity	59
3.5.	Analytical Method for the Estimation of CBP	59
3.5.1.	Chromatographic setup	59
3.5.2.	Mobile Phase Preparation	60
3.5.3.	Preparation of Stock solution	60
3.5.4.	Preparation of standard solutions	60
3.5.5.	Preparation of calibration plot	60
3.5.6.	Validation of HPLC method	60
3.5.6.1.	Linearity	60
3.5.6.2.	Precision	61
3.5.6.3.	Accuracy	61
3.5.6.4.	Sensitivity	61
3.6.	Results and Discussion	62
3.6.1.	Preparation of calibration plot	62
3.6.2.	Validation of HPLC Method	63
3.6.2.1.	Linearity	63
3.6.2.2.	Precision	63
3.6.2.3.	Accuracy	64

Section	Description	Pg. No.
3.6.2.4.	Sensitivity	64
Chapter 4: Preformulation Studies and Preliminary Development		67 – 86
4.1.	Introduction	67
4.2.	Materials and Equipment	67
4.3.	Preformulation	68
4.3.1.	Methods	68
4.3.1.1.	Fourier Transform Infrared spectroscopy (FTIR)	68
4.3.1.2.	Melting point determination	68
4.3.1.3.	Differential scanning calorimetry (DSC)	69
4.3.1.4.	Drug-Excipients compatibility study	69
4.3.2.	Results and Discussion	69
4.3.2.1.	Fourier Transform Infrared spectroscopy (FTIR)	69
4.3.2.2.	Melting point determination	71
4.3.2.3.	Differential scanning calorimetry (DSC) and Drug-Excipients compatibility study	71
4.4.	Feasibility trials of the formulation	72
4.5.	Preliminary optimization of PTX-UDNVs formulation	75
4.6.	Preliminary optimization of CBP-UDNVs formulation	82
Chapter 5: Formulation Development- Paclitaxel UDNVs		87 – 111
5.1.	Introduction	87
5.2.	Materials and Equipment	87
5.3.	Preparation and Optimization of PTX loaded UDNVs	88
5.3.1.	Methods	88
5.3.1.1.	Preparation of PTX loaded UDNVs	88
5.3.1.2.	Quality Target Product Profile (QTPP) of PTX loaded UDNVs and Identification of CQAs	88
5.3.1.3.	Qualitative Risk assessment and Identification of Independent variables (factors)	89
5.3.1.4.	Quantitative risk assessment: Factors Screening Design	90
5.3.1.5.	Formulation optimization using Box–Behnken Response Surface Design	91
5.3.2.	Results and Discussion	92
5.3.2.1.	Quality Target Product Profile (QTPP) of PTX loaded UDNVs and Identification of CQAs	92
5.3.2.2.	Qualitative Risk assessment and Identification of Independent variables (factors)	94
5.3.2.3.	Quantitative risk assessment: Factors Screening Design	96
5.3.2.4.	Formulation optimization using Box–Behnken Response Surface Design	101
5.4.	Preparation of PTX-UDNVs loaded Intravaginal Rod Inserts	110
Chapter 6: Formulation Development- Carboplatin UDNVs		113 – 137
6.1.	Introduction	113

Section	Description	Pg. No.
6.2.	Materials and Equipment	113
6.3.	Preparation and Optimization of CBP loaded UDNVs	114
6.3.1.	Methods	114
6.3.1.1.	Preparation of CBP loaded UDNVs	114
6.3.1.2.	Quality Target Product Profile (QTPP) of CBP loaded UDNVs and Identification of CQAs	114
6.3.1.3.	Qualitative Risk assessment and Identification of Independent variables (factors)	115
6.3.1.4.	Quantitative risk assessment: Factors Screening Design	115
6.3.1.5.	Formulation optimization using Box–Behnken Response Surface Design	117
6.3.2.	Results and Discussion	118
6.3.2.1.	Quality Target Product Profile (QTPP) of CBP loaded UDNVs and Identification of CQAs	118
6.3.2.2.	Qualitative Risk assessment and Identification of Independent variables (factors)	119
6.3.2.3.	Quantitative risk assessment: Factors Screening Design	122
6.3.2.4.	Formulation optimization using Box–Behnken Response Surface Design	127
6.4.	Preparation of CBP-UDNVs loaded Intravaginal Rod Inserts	136
Chapter 7: Formulation Characterization		139 – 165
7.1.	Introduction	139
7.2.	Materials and Equipment	139
7.3.	Characterization of PTX-UDNVs	140
7.3.1.	Methods	140
7.3.1.1.	Vesicle Size and Zeta Potential	140
7.3.1.2.	Entrapment efficiency and Drug loading	140
7.3.1.3.	Deformability of the vesicles	140
7.3.1.4.	Shape and surface morphology using TEM	141
7.3.1.5.	In Vitro drug release study	141
7.3.1.6.	Permeation and Deposition study	142
7.3.1.7.	Physical stability of PTX-UDNVs in IVR	143
7.3.2.	Results and Discussion	143
7.3.2.1.	Vesicle Size and Zeta Potential	143
7.3.2.2.	Entrapment efficiency and Drug loading	145
7.3.2.3.	Deformability of the vesicles	145
7.3.2.4.	Shape and surface morphology using TEM	146
7.3.2.5.	In Vitro drug release study	146
7.3.2.6.	Permeation and Deposition study	149
7.3.2.7.	Physical stability of PTX-UDNVs in IVR	151
7.4.	Characterization of CBP-UDNVs	151
7.4.1.	Methods	151

Section	Description	Pg. No.
7.4.1.1.	Vesicle Size and Zeta Potential	151
7.4.1.2.	Entrapment efficiency and Drug loading	151
7.4.1.3.	Deformability of the vesicles	152
7.4.1.4.	Shape and surface morphology using TEM	152
7.4.1.5.	In Vitro drug release study	153
7.4.1.6.	Permeation and Deposition Study	153
7.4.1.7.	Physical stability of CBP-UDNVs in IVR	154
7.4.2.	Results and Discussion	154
7.4.2.1.	Vesicle Size and Zeta Potential	154
7.4.2.2.	Entrapment efficiency and Drug loading	156
7.4.2.3.	Deformability of the vesicles	156
7.4.2.4.	Shape and surface morphology using TEM	157
7.4.2.5.	In Vitro drug release study	158
7.4.2.6.	Permeation and Deposition Study	161
7.4.2.7.	Physical stability of CBP-UDNVs in IVR	163
Chapter 8: Biocompatibility and Safety Assessment		167 – 179
8.1.	Introduction	167
8.2.	Materials and Methods	169
8.2.1.	Ex-Vivo Histopathology Study	169
8.2.2.	Haemolytic toxicity study	170
8.3.	Results and Discussion	171
8.3.1.	Ex-Vivo Histopathology Study	171
8.3.2.	Haemolytic toxicity study	175
Chapter 9: Cell line studies		181 – 193
9.1.	Introduction	181
9.1.1.	Cytotoxicity study by MTT Assay	181
9.1.2.	In vitro cellular uptake study	182
9.2.	Material and Equipment	182
9.2.1.	Cell Line	182
9.3.	Cell Cytotoxicity study by MTT Assay	183
9.4.	Quantitative cellular uptake analysis by FACS	184
9.5.	Results and Discussion	185
9.5.1.	Cell Cytotoxicity study	185
9.5.2.	Quantitative cellular uptake study	189
Chapter 10: In-Vivo Biodistribution and Efficacy study		195 – 218
10.1.	Introduction	195
10.2.	Materials and Methods	197
10.2.1.	In vivo Biodistribution Study	197
10.2.1.1.	Radiolabelling of Drugs	197
10.2.1.2.	Radiochemical Purity	198
10.2.1.3.	In vitro stability study	199

Section	Description	Pg. No.
10.2.1.4.	DTPA Transchelation Study	199
10.2.1.5.	In vivo biodistribution studies in Rabbits	199
10.2.1.6.	Quantitative systemic absorption study	200
10.2.2.	In vivo efficacy study	200
10.2.2.1.	Experimental setup and Induction of endometrial carcinoma (EC) in Rabbits	201
10.3.	Results and Discussion	202
10.3.1.	In vivo Biodistribution Study	202
10.3.1.1.	Radiochemical purity	202
10.3.1.2.	In vitro stability study	204
10.3.1.3.	DTPA Transchelation Study	205
10.3.1.4.	In vivo biodistribution studies in Rabbits	206
10.3.1.5.	Quantitative systemic absorption study	209
10.3.2.	In vivo efficacy study	211
Chapter 11: Stability Studies		219 – 223
11.1.	Introduction	219
11.2.	Materials and Equipments	219
11.3.	Methods	220
11.4.	Results and Discussion	220
Chapter 12: Summary and Conclusion		225 – 234
12.1.	Introduction	225
12.2.	Analytical methods	227
12.3.	Preformulation Studies and Preliminary Development	227
12.4.	Formulation Development- Paclitaxel UDNVs	228
12.5.	Formulation Development- Carboplatin UDNVs	229
12.6.	Formulation Characterization	230
12.7.	Biocompatibility and Safety Assessment	231
12.8.	Cell line studies	231
12.9.	In-Vivo Biodistribution and Efficacy study	232
12.10.	Stability Studies	233
12.11.	Conclusion	233